Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 17/20 | 0.60 |
| ▸ | CTRC | Q99895 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935884 | 1.00 | PPARG (0.64) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL557511 | 0.95 | CTRC (0.62) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL1565255 | 0.94 | PPARG (0.61) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL4002165 | 0.93 | CTRC (0.64) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL15903011 | 0.93 | CTRC (0.64) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL570688 | 0.93 | CTRC (0.64) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL6342298 | 0.93 | CTRC (0.64) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL11531304 | 0.93 | CTRC (0.64) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL22828775 | 0.93 | CTRC (0.64) | PPARGALOX5PTGESPPARACTRC | |
| SCHEMBL4001414 | 0.93 | CTRC (0.64) | PPARGALOX5PTGESPPARACTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | claimed |
| EP-4031124-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | Reneo Pharmaceuticals, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| CN-114727976-A | Use of PPAR-delta agonists in the treatment of renal disease | 雷内奥制药公司 | 2022-07-08 | — | — | CN | claimed |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | RENEO PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | claimed |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3927718-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | Reneo Pharmaceuticals, Inc. (US) | 2021-12-29 | — | — | EP | claimed |
| EP-3920903-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | Reneo Pharmaceuticals, Inc. (US) | 2021-12-15 | — | — | EP | claimed |
| CN-113747891-A | Use of PPAR delta agonists in the treatment of Fatty Acid Oxidation Disorders (FAOD) | 雷内奥制药公司 | 2021-12-03 | — | — | CN | claimed |
| CN-113710683-A | Use of PPAR-delta agonists in the treatment of mitochondrial myopathy | 雷内奥制药公司 | 2021-11-26 | — | — | CN | claimed |
| WO-2021055725-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | RENEO PHARMACEUTICALS, INC. (US) | 2021-03-25 | — | — | WO | claimed |
| WO-2020163240-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | WO | claimed |
| EP-3634972-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | Teva Czech Industries s.r.o. (CZ) | 2020-04-15 | — | — | EP | claimed |
| WO-2019014286-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2019-01-17 | — | — | WO | claimed |
| CN-110475473-B | Compound containing monoterpene/phenylpropanoid, preparation method and application thereof as pesticide | 奇特利奇公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | RENEO PHARMACEUTICALS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0267048-A2 | Peroxyacids, phenoxyacetate peracid precursors and perhydrolysis system | The Clorox Company (US) | 1988-05-11 | — | — | EP | disclosed |
| EP-0128598-B1 | THERMOPLASTIC MOULDING COMPOSITION | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-05-13 | — | — | EP | disclosed |
| US-4508541-A | DETERGENTS | TEXACO INC. (US) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | PPARG, PPARA, PPARD | PPARG 1/4885ALOX5 1963/4885PTGES 224/4885 |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | PPARG, PPARD, PPARA | PPARG 1/4885ALOX5 987/4885PTGES 400/4885 |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | PPARD, PPARA, MTPN | PPARG 4/4885ALOX5 1875/4885PTGES 929/4885 |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | PPARG 1/4885ALOX5 987/4885PTGES 400/4885 |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | PPARD, ACOX1, CPT1A | PPARG 4/4885ALOX5 374/4885PTGES 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.